The expanding role for small molecules in immuno-oncology.
Journal
Nature reviews. Drug discovery
ISSN: 1474-1784
Titre abrégé: Nat Rev Drug Discov
Pays: England
ID NLM: 101124171
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
12
07
2022
pubmed:
19
8
2022
medline:
4
11
2022
entrez:
18
8
2022
Statut:
ppublish
Résumé
The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although many of these are antibodies directed against additional checkpoint proteins, there is an increasing interest in small-molecule immuno-oncology drugs that address intracellular pathways, some of which have recently entered clinical trials. In parallel, small molecules that target pro-tumorigenic pathways in cancer cells and the tumour microenvironment have been found to have immunostimulatory effects that synergize with the action of ICI antibodies, leading to the approval of an increasing number of regimens that combine such drugs. Combinations with small molecules targeting cancer metabolism, cytokine/chemokine and innate immune pathways, and T cell checkpoints are now under investigation. This Review discusses the recent milestones and hurdles encountered in this area of drug development, as well as our views on the best path forward.
Identifiants
pubmed: 35982333
doi: 10.1038/s41573-022-00538-9
pii: 10.1038/s41573-022-00538-9
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-840Informations de copyright
© 2022. Springer Nature Limited.
Références
Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
pubmed: 11015443
pmcid: 2193311
doi: 10.1084/jem.192.7.1027
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
pubmed: 8596936
doi: 10.1126/science.271.5256.1734
Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
pubmed: 25858804
pmcid: 4400238
doi: 10.1016/j.ccell.2015.03.001
Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies — BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
pubmed: 32242094
doi: 10.1038/s41571-020-0347-5
Sanmamed, M. F. et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42, 640–655 (2015).
pubmed: 26320067
doi: 10.1053/j.seminoncol.2015.05.014
Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035–1043 (2013).
pubmed: 23460534
pmcid: 3590838
doi: 10.1158/1078-0432.CCR-12-2064
Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119–iv142 (2017).
pubmed: 28881921
doi: 10.1093/annonc/mdx225
Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).
pubmed: 32382051
doi: 10.1038/s41572-020-0160-6
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer 8, e000337 (2020).
pubmed: 32209603
pmcid: 7064135
doi: 10.1136/jitc-2019-000337
Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
pubmed: 21639810
doi: 10.1056/NEJMoa1104621
Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.-Y. & Caux, C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J. Immunother. Cancer 7, 85 (2019).
pubmed: 30922400
pmcid: 6437964
doi: 10.1186/s40425-019-0549-5
Lito, P., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401–1409 (2013).
pubmed: 24202393
doi: 10.1038/nm.3392
Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577–592 (2015).
pubmed: 26399658
doi: 10.1038/nrc4000
Ribas, A. et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin. Cancer Res. 26, 46 (2020).
pubmed: 31732523
doi: 10.1158/1078-0432.CCR-18-4180
Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626–636 (2019).
pubmed: 31166680
doi: 10.1056/NEJMoa1904059
Garbe, C. et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment–update 2019. Eur. J. Cancer 126, 159–177 (2020).
pubmed: 31866016
doi: 10.1016/j.ejca.2019.11.015
Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 936–940 (2019).
pubmed: 31171879
pmcid: 8562134
doi: 10.1038/s41591-019-0476-5
Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929–935 (2019).
pubmed: 31171876
doi: 10.1038/s41591-019-0474-7
Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Sci. Transl. Med. 7, 279ra241 (2015). First preclinical evidence of the pro-immunogenic impact of MEK inhibitors.
doi: 10.1126/scitranslmed.aaa4691
Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016).
pubmed: 26944201
doi: 10.1016/j.immuni.2016.01.024
Dushyanthen, S. et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat. Commun. 8, 606 (2017).
pubmed: 28928458
pmcid: 5605577
doi: 10.1038/s41467-017-00728-9
Baumann, D. et al. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat. Commun. 11, 2176 (2020).
pubmed: 32358491
pmcid: 7195409
doi: 10.1038/s41467-020-15979-2
Baumann, D. et al. p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition. J. Immunother. Cancer 9, e002319 (2021).
pubmed: 34285105
pmcid: 8292803
doi: 10.1136/jitc-2020-002319
Dörrie, J. et al. BRAF and MEK inhibitors influence the function of reprogrammed T cells: consequences for adoptive T-cell therapy. Int. J. Mol. Sci. 19, 289 (2018).
pmcid: 5796234
doi: 10.3390/ijms19010289
Ferrucci, P. F. et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J. Immunother. Cancer 8, e001806 (2020).
pubmed: 33361337
pmcid: 7768966
doi: 10.1136/jitc-2020-001806
Gutzmer, R. et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395, 1835–1844 (2020). Clinical trial that fulfilled the concept of synergy between MEK/BRAF inhibition and ICI, resulting in FDA approval of this triple regimen for BRAF-mutated melanoma.
pubmed: 32534646
doi: 10.1016/S0140-6736(20)30934-X
Dummer, R. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat. Med. 26, 1557–1563 (2020).
pubmed: 33020648
doi: 10.1038/s41591-020-1082-2
Dummer, R. et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J. Clin. Oncol. 40, 1428–1438 (2022).
pubmed: 35030011
pmcid: 9061149
doi: 10.1200/JCO.21.01601
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019). First preclinical evidence for synergy of a mutant-KRAS-specific drug with ICI.
pubmed: 31666701
doi: 10.1038/s41586-019-1694-1
Briere, D. M. et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol. Cancer Ther. 20, 975–985 (2021).
pubmed: 33722854
pmcid: 8444277
doi: 10.1158/1535-7163.MCT-20-0462
Łuksza, M. et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551, 517–520 (2017).
pubmed: 29132144
pmcid: 6137806
doi: 10.1038/nature24473
Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849–861 (2019).
pubmed: 31003911
doi: 10.1016/S1470-2045(19)30027-0
Haigis, K. M. KRAS alleles: the devil is in the detail. Trends Cancer 3, 686–697 (2017).
pubmed: 28958387
pmcid: 5824632
doi: 10.1016/j.trecan.2017.08.006
Hack, S. P., Zhu, A. X. & Wang, Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front. Immunol. 11, 598877 (2020).
pubmed: 33250900
pmcid: 7674951
doi: 10.3389/fimmu.2020.598877
Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018). The clinical study presented in this paper is the first to show clinical benefit of combining a drug that inhibits the VEGF/VEGFR pathway with ICI. Although this study provided proof of concept for the VEGF-blocking Ab bevacizumab, the two publications below demonstrate that this synergy could also be achieved by using small-molecule VEGFR inhibitor axitinib.
pubmed: 29863955
doi: 10.1056/NEJMoa1716948
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531
pmcid: 6716603
doi: 10.1056/NEJMoa1816047
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
pubmed: 30779529
doi: 10.1056/NEJMoa1816714
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
pubmed: 33657295
pmcid: 8436591
doi: 10.1056/NEJMoa2026982
Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).
pubmed: 33616314
doi: 10.1056/NEJMoa2035716
Briukhovetska, D. et al. Interleukins in cancer: from biology to therapy. Nat. Rev. Cancer 21, 481–499 (2021).
pubmed: 34083781
pmcid: 8173513
doi: 10.1038/s41568-021-00363-z
Conlon, K. C., Miljkovic, M. D. & Waldmann, T. A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 39, 6–21 (2019).
pubmed: 29889594
pmcid: 6350412
doi: 10.1089/jir.2018.0019
Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: from bench to clinic. Signal. Transduct. Target. Ther. 6, 402 (2021).
pubmed: 34824210
pmcid: 8617206
doi: 10.1038/s41392-021-00791-1
Setrerrahmane, S. & Xu, H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol. Cancer 16, 153 (2017).
pubmed: 28927416
pmcid: 5606116
doi: 10.1186/s12943-017-0721-9
Derynck, R., Turley, S. J. & Akhurst, R. J. TGFβ biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9–34 (2021).
pubmed: 32710082
doi: 10.1038/s41571-020-0403-1
Ouyang, W. & O’Garra, A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50, 871–891 (2019).
pubmed: 30995504
doi: 10.1016/j.immuni.2019.03.020
Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).
pubmed: 28716061
pmcid: 5514481
doi: 10.1186/s40425-017-0257-y
Osipov, A., Saung, M. T., Zheng, L. & Murphy, A. G. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J. Immunother. Cancer 7, 224 (2019).
pubmed: 31439034
pmcid: 6704558
doi: 10.1186/s40425-019-0667-0
Harb, W. A. et al. A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors. J. Clin. Oncol. 35, TPS3110 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.TPS3110
Pfizer. A study of ARRY-382 in combination with pembrolizumab for the treatment of patients with advanced solid tumors: https://www.pfizer.com/study-arry-382-combination-pembrolizumab-treatment-patients-advanced-solid-tumors , (2022).
Smith, B. D. et al. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Mol. Cancer Ther. 20, 2098–2109 (2021).
pubmed: 34433663
doi: 10.1158/1535-7163.MCT-21-0361
Gelderblom, H. et al. Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT). Ann. Oncol. 32, S1233–S1234 (2021). EMSO Congress 2021, Abstr. 1821P.
doi: 10.1016/j.annonc.2021.08.275
Strachan, D. C. et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8
pubmed: 24498562
pmcid: 3902121
doi: 10.4161/onci.26968
Lin, C.-C. et al. Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 80 (Suppl. 16), CT171 (2020).
Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer 4, 540–550 (2004).
pubmed: 15229479
doi: 10.1038/nrc1388
Keeley, E. C., Mehrad, B. & Strieter, R. M. CXC chemokines in cancer angiogenesis and metastases. Adv. Cancer Res. 106, 91–111 (2010).
pubmed: 20399957
pmcid: 3069502
doi: 10.1016/S0065-230X(10)06003-3
Miao, M., De Clercq, E. & Li, G. Clinical significance of chemokine receptor antagonists. Expert. Opin. Drug Metab. Toxicol. 16, 11–30 (2020).
pubmed: 31903790
doi: 10.1080/17425255.2020.1711884
Poeta, V. M., Massara, M., Capucetti, A. & Bonecchi, R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front. Immunol. 10, 379 (2019).
doi: 10.3389/fimmu.2019.00379
Bader, J. E., Voss, K. & Rathmell, J. C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol. Cell 78, 1019–1033 (2020).
pubmed: 32559423
pmcid: 7339967
doi: 10.1016/j.molcel.2020.05.034
Oh, M.-H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Invest. 130, 3865–3884 (2020).
pubmed: 32324593
pmcid: 7324212
doi: 10.1172/JCI131859
O’Sullivan, D., Sanin, D. E., Pearce, E. J. & Pearce, E. L. Metabolic interventions in the immune response to cancer. Nat. Rev. Immunol. 19, 324–335 (2019).
pubmed: 30820043
doi: 10.1038/s41577-019-0140-9
Emberley, E. et al. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. PLoS ONE 16, e0259241 (2021).
pubmed: 34731180
pmcid: 8565744
doi: 10.1371/journal.pone.0259241
Varghese, S. et al. The glutaminase inhibitor CB-839 (Telaglenastat) enhances the antimelanoma activity of T-cell–mediated immunotherapies. Mol. Cancer Ther. 20, 500 (2021).
pubmed: 33361272
doi: 10.1158/1535-7163.MCT-20-0430
Miret, J. J. et al. Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J. Immunother. Cancer 7, 32 (2019).
pubmed: 30728077
pmcid: 6366094
doi: 10.1186/s40425-019-0504-5
Pham, T. N., Liagre, B., Girard-Thernier, C. & Demougeot, C. Research of novel anticancer agents targeting arginase inhibition. Drug Discov. Today 23, 871–878 (2018).
pubmed: 29391126
doi: 10.1016/j.drudis.2018.01.046
Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother. Cancer 5, 101–112 (2017).
pubmed: 29254508
pmcid: 5735564
doi: 10.1186/s40425-017-0308-4
Koyama, T. et al. Phase 1 study of retifanlimab (anti-PD-1) and INCB001158 (arginase inhibitor), alone or in combination, in solid tumors. Ann. Oncol. 32, S302 (2021). Conference abstract MO310-306 JSMO2021 Virtual Congress 2021 the Japanese Society of Medical Oncology Annual Meeting.
doi: 10.1016/j.annonc.2021.05.587
Naing, A. Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours [Abstr. 1621]. Ann. Oncol. 30 (Suppl. 5), v160 (2019).
doi: 10.1093/annonc/mdz244.002
Lu, M. et al. Structure-based discovery of proline-derived arginase inhibitors with improved oral bioavailability for immuno-oncology. ACS Med. Chem. Lett. 12, 1380–1388 (2021).
pubmed: 34527178
pmcid: 8436246
doi: 10.1021/acsmedchemlett.1c00195
Allard, B., Allard, D., Buisseret, L. & Stagg, J. The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611–629 (2020).
pubmed: 32514148
doi: 10.1038/s41571-020-0382-2
Thompson, E. A. & Powell, J. D. Inhibition of the adenosine pathway to potentiate cancer immunotherapy: potential for combinatorial approaches. Annu. Rev. Med. 72, 331–348 (2021).
pubmed: 32903139
doi: 10.1146/annurev-med-060619-023155
Kötzner, L., Huck, B., Garg, S. & Urbahns, K. Small molecules — giant leaps for immuno-oncology. Prog. Med. Chem. 59, 1–62 (2020).
pubmed: 32362326
doi: 10.1016/bs.pmch.2019.11.001
Seitz, L. et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest. New Drugs 37, 711–721 (2019). The potency of this dual A2aR/A2bR inhibitor in combination with the well-tolerated properties in patients provide a perspective for clinical benefit in combination with ICI.
pubmed: 30569245
doi: 10.1007/s10637-018-0706-6
Subudhi, S. K. et al. ARC-6: a phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC). J. Clin. Oncol. 39, 5039–5039 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.5039
Cecchini, M. et al. ARC-3: updated results of etrumadenant (AB928)+modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients. Cancer Res. 81 (Suppl. 13), CT129 (2021).
doi: 10.1158/1538-7445.AM2021-CT129
Han, H., Zhao, L., Yao, W. & Wang, X. Triazolopyrimidines as A2a/A2b inhibitors. International Patent Application WO/2021/041360 (2021).
Fan, P. et al. TT-702, a selective and potent A2B receptor antagonist for the treatment of cancer. Cancer Res. 81 (Suppl. 13), Abstr. 55 (2021).
doi: 10.1158/1538-7445.AM2021-55
Liu, J. & Elzein, E. Adenosine receptor antagonists and uses thereof. International Patent Application WO/2019/173380 (2019).
Du, X. et al. Orally bioavailable small-molecule CD73 inhibitor (OP-5244) reverses immunosuppression through blockade of adenosine production. J. Med. Chem. 63, 10433–10459 (2020).
pubmed: 32865411
doi: 10.1021/acs.jmedchem.0c01086
Lawson, K. V. et al. Discovery of AB680: a potent and selective inhibitor of CD73. J. Med. Chem. 63, 11448 (2020).
pubmed: 32614585
doi: 10.1021/acs.jmedchem.0c00525
Sutimantanapi, D. et al. Blocking adenosine production with ORIC-533, a CD73 inhibitor with best-in-class properties, reverses immunosuppression in high-AMP environments. Cancer Res. 81 (Suppl. 13), Abstr. LB163 (2021).
doi: 10.1158/1538-7445.AM2021-LB163
Manji, G. A. et al. ARC-8: phase I/Ib study to evaluate safety and tolerability of AB680+chemotherapy+zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). J. Clin. Oncol. 39(Suppl. 3), Abstr. 404 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.404
Boison, D. & Yegutkin, G. G. Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell 36, 582–596 (2019).
pubmed: 31821783
pmcid: 7224341
doi: 10.1016/j.ccell.2019.10.007
Opitz, C. A. et al. The therapeutic potential of targeting tryptophan catabolism in cancer. Br. J. Cancer 122, 30–44 (2020).
pubmed: 31819194
doi: 10.1038/s41416-019-0664-6
Muller, A. J., Manfredi, M. G., Zakharia, Y. & Prendergast, G. C. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin. Immunopathol. 41, 41–48 (2019).
pubmed: 30203227
doi: 10.1007/s00281-018-0702-0
Van den Eynde, B. J., van Baren, N. & Baurain, J.-F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu. Rev. Cancer Biol. 4, 241–256 (2020).
doi: 10.1146/annurev-cancerbio-030419-033635
Poncelet, L., Ait-Belkacem, R., Marillier, R., Gomes, B. & Stauber, J. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model. J. Pharm. Biomed. Anal. 170, 220–227 (2019).
pubmed: 30933897
doi: 10.1016/j.jpba.2019.02.038
Balog, A. et al. Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor. Mol. Cancer Ther. 20, 467 (2021). The ongoing phase III study with linrodostat will show whether the lack of success with its predecessor epacadostat was a matter of potency and/or dosage or conceptual issues. Its outcome is likely to have tremendous impact on the entire effort concerning the targeting of metabolic pathways.
pubmed: 33298590
doi: 10.1158/1535-7163.MCT-20-0251
Sadik, A. et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 182, 1252–1270.e1234 (2020).
pubmed: 32818467
doi: 10.1016/j.cell.2020.07.038
Gyulveszi, G. et al. RG70099: a novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment. Cancer Res. 76 (Suppl. 14), Abstr. LB-085 (2016).
doi: 10.1158/1538-7445.AM2016-LB-085
Naing, A. et al. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. J. Immunother. Cancer 8, e000870 (2020).
pubmed: 32843490
pmcid: 7449315
doi: 10.1136/jitc-2020-000870
Schmees, N. et al. Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression. Cancer Res. 79 (Suppl. 13), Abstr. 4454 (2019).
doi: 10.1158/1538-7445.AM2019-4454
Castro, A. et al. AHR inhibitors and uses thereof. International Patent Application WO/2019/036657 (2017).
Palm, N. W. & Medzhitov, R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227, 221–233 (2009).
pubmed: 19120487
doi: 10.1111/j.1600-065X.2008.00731.x
Smith, M. et al. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology 7, e1526250 (2018).
pubmed: 30524908
pmcid: 6279325
doi: 10.1080/2162402X.2018.1526250
Kaczanowska, S., Joseph, A. M. & Davila, E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93, 847–863 (2013). This review article explains the reasons underlying the difficulties of translating promising data with TLR agonists obtained in preclinical mouse models into a therapeutic window for cancer patients.
pubmed: 23475577
pmcid: 3656332
doi: 10.1189/jlb.1012501
Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 949–964 (2009).
pubmed: 20563267
doi: 10.2217/imt.09.70
Rehli, M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol. 23, 375–378 (2002).
pubmed: 12133792
doi: 10.1016/S1471-4906(02)02259-7
Anwar, M. A., Shah, M., Kim, J. & Choi, S. Recent clinical trends in Toll-like receptor targeting therapeutics. Med. Res. Rev. 39, 1053–1090 (2019).
pubmed: 30450666
doi: 10.1002/med.21553
Deane, J. A. et al. Identifıcation and characterization of LHC165, a TLR7 agonist designed for localized intratumoral therapies. Cancer Res. 81 (Suppl. 13), Abstr. 4128 (2019).
doi: 10.1158/1538-7445.AM2019-4128
Curigliano, G. et al. Phase I study of LHC165±spartalizumab (PDR001) in patients (pts) with advanced solid tumors. Cancer Res 81 (Suppl. 13), Abstr. CT103 (2021).
doi: 10.1158/1538-7445.AM2021-CT103
Klempner, S. et al. A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers. J. Immunother. Cancer 9 (Suppl. 2), A426 (2021). Abstr. 393.
doi: 10.1136/jitc-2021-SITC2021.393
Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).
pubmed: 33243969
pmcid: 7691519
doi: 10.1038/s41419-020-03221-2
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).
pubmed: 31355488
pmcid: 6814203
doi: 10.1111/imr.12765
Ding, C., Song, Z., Shen, A., Chen, T. & Zhang, A. Small molecules targeting the innate immune cGAS–STING–TBK1 signaling pathway. Acta Pharm. Sin. B 10, 2272–2298 (2020).
pubmed: 33354501
pmcid: 7745059
doi: 10.1016/j.apsb.2020.03.001
Motedayen Aval, L., Pease, J. E., Sharma, R. & Pinato, D. J. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J. Clin. Med. 9, 3323 (2020).
pmcid: 7602874
doi: 10.3390/jcm9103323
Bratulic, A. Novartis drops Aduro’s STING agonist ADU-S100 from portfolio, https://www.firstwordpharma.com/node/1688694?tsid=17 (2019).
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. & Kroemer, G. Trial watch: STING agonists in cancer therapy. OncoImmunology 9, 1777624 (2020).
pubmed: 32934881
pmcid: 7466854
doi: 10.1080/2162402X.2020.1777624
Luke, J. J. et al. 598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours. Ann. Oncol. 31, S500 (2020).
doi: 10.1016/j.annonc.2020.08.712
Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
pubmed: 30405246
doi: 10.1038/s41586-018-0705-y
Zhang, R., Kang, R. & Tang, D. The STING1 network regulates autophagy and cell death. Signal. Transduct. Target. Ther. 6, 208 (2021).
pubmed: 34078874
pmcid: 8172903
doi: 10.1038/s41392-021-00613-4
Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J. & Luke, J. J. STING agonists as cancer therapeutics. Cancer 13, 2695 (2021).
doi: 10.3390/cancers13112695
Larkin, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397 (2017).
pubmed: 28615418
doi: 10.4049/jimmunol.1601999
Onyedibe, K. I., Wang, M. & Sintim, H. O. ENPP1, an old enzyme with new functions, and small molecule inhibitors — a STING in the tale of ENPP1. Molecules 24, 4192 (2019).
pmcid: 6891441
doi: 10.3390/molecules24224192
Motwani, M., Pesiridis, S. & Fitzgerald, K. A. DNA sensing by the cGAS–STING pathway in health and disease. Nat. Rev. Genet. 20, 657–674 (2019).
pubmed: 31358977
doi: 10.1038/s41576-019-0151-1
Baird, J. MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo. Society for Immunotherapy of Cancer 2018 Annual Meeting P410 (2018).
Weston, A. et al. Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway. Cancer Res. 79 (Suppl. 13), Abstr. 3077 (2019).
doi: 10.1158/1538-7445.AM2019-3077
Weston, A. S. et al. SR8541A is a potent inhibitor of ENPP1 and exhibits dendritic cell mediated antitumor activity. Cancer Res. 80 (suppl. 16), Abstr. LB-118 (2020).
doi: 10.1158/1538-7445.AM2020-LB-118
Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548–569 (2021).
pubmed: 33833439
pmcid: 8029610
doi: 10.1038/s41577-021-00524-z
Hemphill, W. O. et al. TREX1 as a novel immunotherapeutic target. Front. Immunol. 12, 660184 (2021).
pubmed: 33868310
pmcid: 8047136
doi: 10.3389/fimmu.2021.660184
Hopp, A.-K. & Hottiger, M. O. Uncovering the invisible: mono-ADP-ribosylation moved into the spotlight. Cells 10, 680 (2021).
pubmed: 33808662
pmcid: 8003356
doi: 10.3390/cells10030680
Gozgit, J. M. et al. RBN-2397: a potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells. Cancer Res. 81 (Suppl. 13), Abstr. 48 (2021).
doi: 10.1158/1538-7445.AM2021-48
Mérida, I., Andrada, E., Gharbi, S. I. & Ávila-Flores, A. Redundant and specialized roles for diacylglycerol kinases α and ζ in the control of T cell functions. Sci. Signal. 8, re6 (2015).
pubmed: 25921290
doi: 10.1126/scisignal.aaa0974
Shui, J.-W. et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses. Nat. Immunol. 8, 84–91 (2007).
pubmed: 17115060
doi: 10.1038/ni1416
Stromnes, I. M. et al. Abrogation of Src homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. J. Immunol. 189, 1812 (2012).
pubmed: 22798667
doi: 10.4049/jimmunol.1200552
Brownlie, R. J., Wright, D., Zamoyska, R. & Salmond, R. J. Deletion of PTPN22 improves effector and memory CD8
doi: 10.1172/jci.insight.127847
Cubas, R. et al. Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy. J. Immunother. Cancer 8, e001439 (2020).
pubmed: 33127657
pmcid: 7604869
doi: 10.1136/jitc-2020-001439
Loeser, S. et al. Spontaneous tumor rejection by CBL-B–deficient CD8
pubmed: 17403934
pmcid: 2118550
doi: 10.1084/jem.20061699
Chuang, H.-C., Wang, X. & Tan, T.-H. Chapter seven – MAP4K family kinases in immunity and inflammation. Adv. Immunol. 129, 277–314 (2016).
pubmed: 26791862
doi: 10.1016/bs.ai.2015.09.006
Magiera-Mularz, K. et al. Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience 24, 101960 (2021).
pubmed: 33437940
doi: 10.1016/j.isci.2020.101960
Ramachandra, M. et al. Small molecule immune checkpoint antagonists for cancer therapy. EFMC-ISMC 2018–2025th EFMC International Symposium on Medicinal Chemistry, Abstr. LE005 (2018).
Radhakrishnan, V. et al. Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1 [Abstr. 1209P]. Ann. Oncol. 30 (Suppl. 5), v494 (2019).
doi: 10.1093/annonc/mdz253.035
Sasikumar, P. G. et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun. Biol. 4, 699 (2021).
pubmed: 34103659
pmcid: 8187357
doi: 10.1038/s42003-021-02191-1
ElTanbouly, M. A., Croteau, W., Noelle, R. J. & Lines, J. L. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin. Immunol. 42, 101308 (2019).
pubmed: 31604531
pmcid: 7233310
doi: 10.1016/j.smim.2019.101308
Park, J.-J. et al. Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nat. Commun. 12, 1222 (2021).
pubmed: 33619272
pmcid: 7900207
doi: 10.1038/s41467-021-21410-1
Wu, L. Discovery of INCB86550: a potent, orally bioavailable small molecule inhibitor of PDL1 for the treatment of cancer. Cancer Res. 81 (Suppl. 13), Abstr. ND01 (2021).
doi: 10.1158/1538-7445.AM2021-ND01
Boomer, J. S. & Tan, T.-H. Functional interactions of HPK1 with adaptor proteins. J. Cell. Biochem. 95, 34–44 (2005).
pubmed: 15770651
doi: 10.1002/jcb.20401
Bartolo, V. D. et al. A novel pathway down-modulating T cell activation involves HPK-1–dependent recruitment of 14-3-3 proteins on SLP-76. J. Exp. Med. 204, 681–691 (2007).
pubmed: 17353368
pmcid: 2137917
doi: 10.1084/jem.20062066
Alzabin, S. et al. Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response. Cancer Immunol. Immunother. 59, 419 (2009). This is the preclinical study that eventually helped put MAP4K1 inhibition on the IO agenda.
pubmed: 19787351
pmcid: 2798028
doi: 10.1007/s00262-009-0761-0
Sawasdikosol, S., Pyarajan, S., Alzabin, S., Matejovic, G. & Burakoff, S. J. Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. J. Biol. Chem. 282, 34693–34699 (2007).
pubmed: 17895239
doi: 10.1074/jbc.M707425200
Hernandez, S. et al. The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function. Cell Rep. 25, 80–94 (2018).
pubmed: 30282040
doi: 10.1016/j.celrep.2018.09.012
Linney, I. D. & Kaila, N. Inhibitors of immuno-oncology target HPK1–a patent review (2016 to 2020). Expert Opin. Ther. Pat. 31, 893–910 (2021).
pubmed: 33956554
doi: 10.1080/13543776.2021.1924671
Si, J. et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell 38, 551–566.e511 (2020).
pubmed: 32860752
doi: 10.1016/j.ccell.2020.08.001
Jin, J. et al. Heterobifunctional compounds as degraders of HPK1. International Patent Application WO/2020/227325A1 (2019).
You, D. et al. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. J. Immunother. Cancer 9, e001402 (2021).
pubmed: 33408094
pmcid: 7789447
doi: 10.1136/jitc-2020-001402
Leder, G. et al. Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1. Cancer Res. 81 (Suppl. 13), Abstr. 1722 (2021).
doi: 10.1158/1538-7445.AM2021-1722
Vara, B. A. et al. Discovery of diaminopyrimidine carboxamide HPK1 inhibitors as preclinical immunotherapy tool compounds. ACS Med. Chem. Lett. 12, 653–661 (2021).
pubmed: 33859804
pmcid: 8040257
doi: 10.1021/acsmedchemlett.1c00096
Degnan, A. P. et al. Discovery of orally active isofuranones as potent, selective inhibitors of hematopoetic progenitor kinase 1. ACS Med. Chem. Lett. 12, 443–450 (2021).
pubmed: 33732413
pmcid: 7957935
doi: 10.1021/acsmedchemlett.0c00660
Yu, E. C. et al. Identification of potent reverse indazole inhibitors for HPK1. ACS Med. Chem. Lett. 12, 459–466 (2021).
pubmed: 33738073
pmcid: 7957946
doi: 10.1021/acsmedchemlett.0c00672
Ciccone, D. et al. A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model. Eur. J. Cancer 138, S20 (2020).
doi: 10.1016/S0959-8049(20)31118-7
Ciccone, D. et al. A highly selective and potent HPK1 inhibitor induces robust tumor growth inhibition as a single agent and in combination with anti-PD1 in multiple syngeneic tumor models. AACR Annual Meeting 2021 Poster https://www.nimbustx.com/wp-content/uploads/AACR-2021-POSTER.pdf (2021).
Ishisaka, M. & Hara, H. The roles of diacylglycerol kinases in the central nervous system: review of genetic studies in mice. J. Pharmacol. Sci. 124, 336–343 (2014).
pubmed: 24599142
doi: 10.1254/jphs.13R07CR
Arranz-Nicolás, J. et al. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program. Cancer Immunol. Immunother. 70, 3277–3289 (2021).
pubmed: 33837851
doi: 10.1007/s00262-021-02924-5
Chauveau, A., Le Floc’h, A., Bantilan, N. S., Koretzky, G. A. & Huse, M. Diacylglycerol kinase α establishes T cell polarity by shaping diacylglycerol accumulation at the immunological synapse. Sci. Signal. 7, ra82 (2014).
pubmed: 25161317
pmcid: 4993625
doi: 10.1126/scisignal.2005287
de Chaffoy de Courcelles, D. et al. The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation: a biochemical and functional analysis using the novel diacylglycerol kinase inhibitor, R 59 949. J. Biol. Chem. 264, 3274–3285 (1989).
pubmed: 2536741
doi: 10.1016/S0021-9258(18)94063-9
de Chaffoy de Courcelles, D. C., Roevens, P. & Van Belle, H. R 59 022, a diacylglycerol kinase inhibitor. Its effect on diacylglycerol and thrombin-induced C kinase activation in the intact platelet. J. Biol. Chem. 260, 15762–15770 (1985).
pubmed: 2999135
doi: 10.1016/S0021-9258(17)36324-X
Baldanzi, G. et al. SAP-mediated inhibition of diacylglycerol kinase α regulates TCR-induced diacylglycerol signaling. J. Immunol. 187, 1002476 (2011).
doi: 10.4049/jimmunol.1002476
Prinz, P. U. et al. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8
Moon, E. K. et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors. Clin. Cancer Res. 20, 4262 (2014).
pubmed: 24919573
pmcid: 4134701
doi: 10.1158/1078-0432.CCR-13-2627
Liu, K. et al. A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response. J. Lipid Res. 57, 368–379 (2016).
pubmed: 26768655
pmcid: 4766986
doi: 10.1194/jlr.M062794
Arranz-Nicolás, J. et al. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals. Cancer Immunol. Immunother. 67, 965–980 (2018).
pubmed: 29572701
doi: 10.1007/s00262-018-2154-8
Dominguez, C. L. et al. Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov. 3, 782–797 (2013).
pubmed: 23558954
pmcid: 3710531
doi: 10.1158/2159-8290.CD-12-0215
Fu, L. et al. DGKA mediates resistance to PD-1 blockade. Cancer Immunol. Res. 9, 371 (2021).
pubmed: 33608256
doi: 10.1158/2326-6066.CIR-20-0216
Velaparthi, U. et al. Substituted naphthyridinone compounds useful as T cell activators. International Patent Application WO/2020/006018 (2020).
Velnati, S. et al. Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors. J. Enzym. Inhib. Med. Chem. 35, 96–108 (2020).
doi: 10.1080/14756366.2019.1684911
Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211–216 (2000).
pubmed: 10646608
doi: 10.1038/35003228
Chiang, Y. J. et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216–220 (2000).
pubmed: 10646609
doi: 10.1038/35003235
Li, D. et al. Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation. J. Immunol. 173, 7135 (2004).
pubmed: 15585834
doi: 10.4049/jimmunol.173.12.7135
Karwacz, K. et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8
pubmed: 21739608
pmcid: 3191120
doi: 10.1002/emmm.201100165
Chiang, J. Y., Jang, I. K., Hodes, R. & Gu, H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J. Clin. Invest. 117, 1029–1036 (2007).
pubmed: 17364027
pmcid: 1810570
doi: 10.1172/JCI29472
Wirnsberger, G. et al. Inhibition of CBLB protects from lethal Candida albicans sepsis. Nat. Med. 22, 915–923 (2016).
pubmed: 27428901
pmcid: 6209141
doi: 10.1038/nm.4134
Hinterleitner, R. et al. Adoptive transfer of siRNA Cblb-silenced CD8
pubmed: 22962608
pmcid: 3433477
doi: 10.1371/journal.pone.0044295
Jajour, J., Havens, K. & Krostag, A. R. Cblb endonuclease variants, compositions, and methods of use. International Patent Application WO/2020/072059 (2020).
Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156 (2015).
pubmed: 26424571
pmcid: 4790757
doi: 10.1126/scitranslmed.aac5530
Chirino, L. M. et al. TAM receptors attenuate murine NK-cell responses via E3 ubiquitin ligase Cbl-b. Eur. J. Immunol. 50, 48–55 (2020).
pubmed: 31531847
doi: 10.1002/eji.201948204
Rountree, R. et al. Small molecule inhibition of the ubiquitin ligase CBL-B results in potent T and NK cell mediated anti-tumor response. Cancer Res. 81 (Suppl. 13), Abstr. 1595 (2021). The preclinical data on the CBL-B inhibitor developed by Nurix demonstrates that this is a very powerful small-molecule ICI. The unanswered question, given its capacity to inhibit both CBL-B and C-CBL, is whether it will show a therapeutic window in patients.
doi: 10.1158/1538-7445.AM2021-1595
Naramura, M. et al. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 3, 1192–1199 (2002).
pubmed: 12415267
doi: 10.1038/ni855
Xu, F. et al. Ablation of Cbl-b and c-Cbl in dendritic cells causes spontaneous liver cirrhosis via altering multiple properties of CD103
pubmed: 35354799
pmcid: 8967913
doi: 10.1038/s41420-022-00953-2
Lorenz, U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 228, 342–359 (2009).
pubmed: 19290938
pmcid: 2669678
doi: 10.1111/j.1600-065X.2008.00760.x
Chen, Y.-N. P. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148–152 (2016). A pioneering example of a potent and selective phosphatase inhibitor, raising hope that the same can also be achieved for the more immune-specific phosphatases SHP1 and PTPN22.
pubmed: 27362227
doi: 10.1038/nature18621
LaMarche, M. J. et al. Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer. J. Med. Chem. 63, 13578–13594 (2020).
pubmed: 32910655
doi: 10.1021/acs.jmedchem.0c01170
Liu, C. et al. Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clin. Cancer Res. 27, 342 (2021).
pubmed: 33046519
doi: 10.1158/1078-0432.CCR-20-2718
Quintana, E. et al. Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment. Cancer Res. 80, 2889 (2020).
pubmed: 32350067
doi: 10.1158/0008-5472.CAN-19-3038
Mullard, A. Phosphatases start shedding their stigma of undruggability. Nat. Rev. Drug Discov. 17, 847–849 (2018).
pubmed: 30482950
doi: 10.1038/nrd.2018.201
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
pubmed: 34986285
doi: 10.1056/NEJMoa2109970
Mullard, A. LAG3 pushes immuno-oncology’s leading edge. Nat. Rev. Drug Discov. 21, 167–169 (2022). This recent commentary provides a vivid account of the dilemmas, hopes and fears faced by all biotech and pharma companies investing in IO drug development.
pubmed: 35177834
doi: 10.1038/d41573-022-00036-y
Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).
pubmed: 22186141
doi: 10.1158/0008-5472.CAN-11-1620
Chau, C. H., Steeg, P. S. & Figg, W. D. Antibody–drug conjugates for cancer. Lancet 394, 793–804 (2019).
pubmed: 31478503
doi: 10.1016/S0140-6736(19)31774-X
Patel Ravi, B. et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci. Transl. Med. 13, eabb3631 (2021).
pubmed: 34261797
pmcid: 8449934
doi: 10.1126/scitranslmed.abb3631
Pende, D. et al. Killer Ig-Like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front. Immunol. 10, 1179 (2019).
pubmed: 31231370
pmcid: 6558367
doi: 10.3389/fimmu.2019.01179
van Hall, T. et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J. Immunother. Cancer 7, 263 (2019).
pubmed: 31623687
pmcid: 6798508
doi: 10.1186/s40425-019-0761-3